Organogenesis Holdings Inc. (ORGO) Revenue History
Annual and quarterly revenue from 2016 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ORGO Revenue Growth
Revenue Breakdown (FY 2025)
ORGO's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ORGO Revenue Analysis (2016–2025)
As of May 7, 2026, Organogenesis Holdings Inc. (ORGO) generated trailing twelve-month (TTM) revenue of $563.9 million, reflecting explosive growth of +78.1% year-over-year. The most recent quarter (Q4 2025) recorded $225.6 million in revenue, up 49.5% sequentially.
Looking at the longer-term picture, ORGO's 5-year compound annual growth rate (CAGR) stands at +10.8%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $564.2 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ORGO's business is primarily driven by Product (100%), and Grant (0%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MDXG (+10.5% YoY), NVCR (+8.5% YoY), and TELA (+12.2% YoY), ORGO has outperformed the peer group in terms of revenue growth. Compare ORGO vs MDXG →
ORGO Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ORGOCurrent | $564M | +78.1% | +10.8% | 7.9% | |
 MDXG | $419M | +10.5% | +11.0% | 15.3% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 TELA | $69M | +12.2% | +35.0% | -49.2% | |
 APOG | $1.4B | +3.2% | +2.7% | 6.0% | |
 IONS | $944M | +47.5% | +5.3% | -40.5% |
ORGO Historical Revenue Data (2016–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $564.2M | +17.0% | $0 | - | $44.7M | 7.9% |
| 2024 | $482.0M | +11.3% | $366.3M | 76.0% | $-1,283,000 | -0.3% |
| 2023 | $433.1M | -3.9% | $326.7M | 75.4% | $12.5M | 2.9% |
| 2022 | $450.9M | -3.5% | $345.9M | 76.7% | $22.3M | 4.9% |
| 2021 | $467.4M | +38.2% | $353.2M | 75.6% | $72.2M | 15.5% |
| 2020 | $338.3M | +29.6% | $251.0M | 74.2% | $26.7M | 7.9% |
| 2019 | $261.0M | +34.9% | $185.0M | 70.9% | $-29,854,000 | -11.4% |
| 2018 | $193.4M | - | $124.6M | 64.4% | $-51,556,000 | -26.7% |
| 2017 | $0 | - | $-4,591,834 | - | $-4,591,834 | - |
| 2016 | $0 | - | $-208,698 | - | $209K | - |
See ORGO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ORGO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ORGO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonORGO — Frequently Asked Questions
Quick answers to the most common questions about buying ORGO stock.
Is ORGO's revenue growth accelerating or slowing?
ORGO revenue is accelerating at +78.1% year-over-year, exceeding the 5-year CAGR of +10.8%. TTM revenue reached $564M. Growth momentum has increased versus prior periods.
What is ORGO's long-term revenue growth rate?
Organogenesis Holdings Inc.'s 5-year revenue CAGR of +10.8% reflects the sustained expansion pattern. Current YoY growth of +78.1% is above this long-term average.
How is ORGO's revenue distributed by segment?
ORGO reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2016-2025 are available for download. Segment mix reveals concentration and diversification trends.